New drug combo targets aggressive bone cancer
NCT ID NCT04067115
Summary
This study tested a new combination of two drugs, trabectedin and irinotecan, for patients with advanced Ewing sarcoma that had returned or stopped responding to other treatments. The main goals were to find the safest dose and see if the drugs could shrink tumors. Researchers also used a special PET scan to see how the drugs affected the cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital / Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Children's Hospital of Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
National Cancer Institute
Bethesda, Maryland, 20892, United States
-
University of Michigan
Ann Arbor, Michigan, 48106, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19105, United States
Conditions
Explore the condition pages connected to this study.